



Combination of neoantigen DNA plasmid vaccine VB10.NEO and bempegaldesleukin (NKTR-214) induces strong neoantigen-specific T cell responses and sustained tumor regression in pre-clinical models

Abstract #2256

S. Granum¹, H. Zell-Flagstad¹, A. Beraas¹, L. Skullerud¹, E. Müller¹, M. Axelsen¹, K. Schjetne¹, J. Zalevsky², A.B. Fredriksen¹

¹Vaccibody AS, Oslo, Norway; ²Nektar Therapeutics, San Francisco, CA


BACKGROUND





CONCLUSIONS

- Combination of VB10.NEO and bempegaldesleukin (NKTR-214) synergizes to elicit greater breadth and depth of neoantigen-specific T cell responses than each individual treatment.
- The synergistic effect was observed in both CD4 and CD8 T cells, and most pronounced on CD8 T cell responses, further supporting the combination's potential to induce strong immunogenic CD8+ T cell responses.
- VB10.NEO in combination with bempegaldesleukin (NKTR-214) and anti-PD-1 induce rapid, complete and durable tumor regression of small tumors and long-lasting stabilization of large tumors supporting the rationale for examining the combination clinically.
- A phase I clinical trial in squamous cell carcinoma of the head and neck (SCCHN) patients is planned to start 2019.


VACCINATIONS – ELISPOT





EX VIVO T CELL RESPONSES



THERAPEUTIC TUMOR CHALLENGE




TUMOR PROTECTIVE IMMUNE RESPONSES



vaccibody

NEKTAR



Scan me